Title : Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.

Pub. Date : 2020 Sep

PMID : 32683457






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CYP3A4 is the main enzyme responsible for SMIs metabolism, and strong CYP3A4 inhibitors, such azoles, could increase drug exposure and toxicity; therefore dose adjustments (venetoclax, quizartinib, and ivosidenib) or alternative therapies or close monitoring (glasdegib, midostaurin, and gilteritinib) are recommended. glasdegib cytochrome P450 family 3 subfamily A member 4 Homo sapiens
2 CYP3A4 is the main enzyme responsible for SMIs metabolism, and strong CYP3A4 inhibitors, such azoles, could increase drug exposure and toxicity; therefore dose adjustments (venetoclax, quizartinib, and ivosidenib) or alternative therapies or close monitoring (glasdegib, midostaurin, and gilteritinib) are recommended. glasdegib cytochrome P450 family 3 subfamily A member 4 Homo sapiens